New pill could reduce blood transfusions for thalassemia patients

NCT ID NCT06302491

First seen Mar 02, 2026 · Last updated May 16, 2026 · Updated 11 times

Summary

This study tests an oral drug called AND017 in 64 adults with β-thalassemia, a blood disorder that often requires lifelong transfusions. Participants receive either AND017 or a placebo alongside standard care. The goal is to see if the drug safely raises hemoglobin levels and reduces the need for blood transfusions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangxi Medical University No.1 Affiliated Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

    Contact

  • Hainan General Hospital

    RECRUITING

    Haikou, Hainan, 570203, China

    Contact

  • Liuzhou People's Hospital

    RECRUITING

    Liuzhou, Guangxi, 545006, China

    Contact

  • Maoming People's Hospital

    RECRUITING

    Maoming, Guangdong, 525000, China

    Contact

  • Nanfang Hospital Southern Medical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510515, China

    Contact

Conditions

Explore the condition pages connected to this study.